摘要
目的探讨醒脑静注射液联合倍他司汀治疗循环缺血性眩晕的疗效及其对血清降钙素基因相关肽(CGRP)、内皮素-1(ET-1)水平的影响。方法120例后循环缺血性眩晕患者,采用随机数字表法分为参比组和研究组,各60例。参比组患者给予盐酸倍他司汀注射液治疗,研究组患者在参比组的基础上给予醒脑静注射液治疗。比较两组临床疗效及治疗前后生化指标[血管内皮生长因子(VEGF)、CGRP、ET-1、ET-1/CGRP]、眩晕情况[眩晕评定量表评分系统(DARS)评分、眩晕障碍量表(DHI)评分]。结果研究组治疗总有效率为93.33%,高于参比组的78.33%,差异有统计学意义(P<0.05)。治疗2周后,两组VEGF、ET-1、ET-1/CGRP水平均低于治疗前,CGRP高于治疗前,且研究组VEGF(24.65±4.71)ng/L、ET-1(134.58±11.76)ng/L、ET-1/CGRP(4.62±0.70)低于参比组的(38.74±5.29)ng/L、(165.79±14.82)ng/L、(8.46±0.58),CGRP(31.62±4.70)ng/L高于参比组的(25.46±3.58)ng/L,差异均有统计学意义(P<0.05)。治疗2周后,两组DARS评分、DHI评分均低于治疗前,且研究组DARS评分(2.76±0.43)分、DHI评分(52.39±4.12)分低于参比组的(4.58±0.39)、(69.70±8.45)分,差异有统计学意义(P<0.05)。结论醒脑静注射液联合倍他司汀可改善后循环缺血性眩晕患者的生化指标水平,减轻眩晕症状,疗效显著。
Objective To discuss the efficacy of Xingnaojing injection combined with betahistine in the treatment of posterior circulation ischemic vertigo and its influence on serum calcitonin gene-related peptide(CGRP)and endothelin-1(ET-1).Methods A total of 120 patients with posterior circulation ischemic vertigo were divided into the reference group and the research group according to the random numerical table,with 60 patients in each group.The reference group was treated with betahistine hydrochloride injection,and the research group was treated with Xingnaojing injection on the basis of the reference group.Both groups were compared in terms of clinical efficacy,biochemical indexes[vascular endothelial growth factor(VEGF),calcitonin gene-related peptide(CGRP),endothelin-1(ET-1),ET-1/CGRP],vertigo[dizziness assessment rating scale(DARS)score,dizziness handicap inventory(DHI)score]before and after treatment.Results The total effective rate of the research group was 93.33%,which was higher than that of 78.33%in the reference group,and the difference was statistically significant(P<0.05).After 2 weeks of treatment,the levels of VEGF,ET-1 and ET-1/CGRP in the two groups were lower than those before treatment in this group,while CGRP was higher than that before treatment in this group;the research group had VEGF of(24.65±4.71)ng/L,ET-1 of(134.58±11.76)ng/L,and ET-1/CGRP of(4.62±0.70),which were lower than those of(38.74±5.29)ng/L,(165.79±14.82)ng/L,and(8.46±0.58)in the reference group;CGRP of(31.62±4.70)ng/L in the research group was higher than that of(25.46±3.58)ng/L in the reference group;the differences were statistically significant(P<0.05).After 2 weeks of treatment,DARS score and DHI score of the two groups were lower than thoes before treatment in this group;DARS score and DHI score of the research group were(2.76±0.43)and(52.39±4.12)points,which were lower than those of(4.58±0.39)and(69.70±8.45)points in the reference group;the differences were statistically significant(P<0.05).Conclusion Xingnaojing injection combined with betahistine can improve the level of biochemical indexes and reduce the symptoms of vertigo in patients with posterior circulation ischemic vertigo.
作者
田丽丽
TIAN Li-li(Siping Geo Encephalopathy Hospital,Siping 136000,China)
出处
《中国现代药物应用》
2023年第7期113-116,共4页
Chinese Journal of Modern Drug Application
关键词
后循环缺血性眩晕
醒脑静注射液
倍他司汀
内皮素-1
降钙素基因相关肽
Posterior circulation ischemic vertigo
Xingnaojing injection
Betahistine
Endothelin-1
Calcitonin gene-related peptide
